Welcome

The Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID) was established by the Department of Medicine to support both fundamental and translational research on human disease.

It houses up to 250 scientists working within 25 research groups. Our work focusses on understanding the pathogenesis and improving the management of immune-related disorders and transforming our understanding of how the infectious agents interact with humans.

CITIID transforms immunity and infection research in Cambridge by providing researchers with advanced facilities that are in close proximity and enable them to optimise their work on human immune, inflammatory and infectious diseases. By bringing together its clinical capabilities and key industry partners, CITIID is also well-placed to drive therapeutic breakthroughs, improve patient outcomes and advance population health both in the UK and abroad.

CITIID News

• Single-cell transcriptomics and proteomics profiling of COVID19 samples reveals immune and HSPC changes that are differentially associated with disease severity -
• Infographics and risk factors associated with seroprevalence of SARS-CoV-2 antibodies in HCWs - As a component of our COVID research we conducted a seroepidemiology study to measure exposure to SARS-CoV-2 at Addenbrookes hospital.…
• Genomics study identifies routes of transmission of coronavirus in care homes -
• Department of Medicine Scientists launch a pre-emptive strike on deadly post-transplant infection - Dr Ian Groves The Wills/Sinclair group have just published on a potential new treatment to protect immunosuppressed patients from human…
• Lab-grown ‘mini-bile ducts’ used to repair human livers in regenerative medicine first -
• Cambridge Festival trailer – Dr Giles Yeo -
• Study highlights risk of new SARS-CoV-2 mutations emerging during chronic infection -
• SAFETY SCREENS How COVID-19 testing is helping keep Cambridge students – and the wider local population – safe -
• Pfizer BioNTech vaccine likely to be effective against B1.1.7 strain of SARS-CoV-2 -
• Likelihood of severe and ‘long’ COVID may be established very early on following infection -